(Reuters) - Johnson & Johnson said on Monday John Reed will take the role of executive vice president of pharmaceuticals, research and development, effective April 3.
(Reuters) – Johnson & Johnson said on Monday John Reed will take the role of executive vice president of pharmaceuticals, research and development, effective April 3.
Reed, 64, will replace William Hait, who was appointed the interim head of the unit in August 2022.
Reed has previously served in executive positions for drugmakers Sanofi SA and Roche Holding AG.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
